Antipsychotic medications are the most common cause of tardive dyskinesia (TD), a condition that may cause involuntary bodily movements. Vesicular monoamine transporter type 2 (VMAT2) inhibitors represent a treatment option that may reduce the symptoms of this movement disorder. In this article, Joseph Jankovic, MD, professor in the Department of Neurology and director of the Parkinson’s Disease Center and Movement Disorders Clinic at Baylor College of Medicine in Houston, Texas, discusses clinical considerations in the use of VMAT2 inhibitors for the treatment of TD.
Special Collections
Clinician POV
Reviewed August 2022
George A. Keepers, MD, the Elda V. Carruthers Professor and Chair, Department of Psychiatry, Oregon Health & Science University, Portland, provides insight for guiding practitioners in the optimal use of long-acting injectable antipsychotics in adults with schizophrenia.
